Additional PET/CT Tracer to Detect Prostate Cancer


Researchers identify 18F-PMSA-1007 as an equally effective radiopharmaceutical for detecting prostate cancer.

Researchers have identified a second radiopharmaceutical that nuclear medicine departments can keep in mind when staging prostate cancer.

According to a study published in the April issue of the Journal of Nuclear Medicine, investigators in Israel determined 18fluorine prostate-specific membrane antigen-1007 (18F-PMSA-1007) can accurately pinpoint malignant prostate cancer lesions.

The team, led by Einat Evan-Sapir, M.D., Ph.D., from Tel Aviv Sourasky Medical Center, said this additional radiopharmaceutical likely has a longer half-life and better spatial resolution than 68gallium-PSMA-11 (68Ga-PMSA-11). According to the study details, 18F-PMSA-1007’s half-life is 110 minutes, and 68Ga-PMSA-11’s is 68 minutes. 68Ga-PSMA-11 also emits a higher-energy positron. 

To determine efficacy, the team compared how well 18F- PMSA-1007 diagnosed prostate cancer to how well 68Ga-PSMA-11 performed with PET/CT scans. They evaluated 16 patients who were awaiting radical prostatectomy for newly-diagnosed intermediate- or high-risk prostate cancer. They, then, compared the outcomes with both radiopharmaceuticals with the gold standard of histopathologic findings.

Both 18F-PMSA-1007 and 68Ga-PMSA-11 identified the same location of radiolabeled PSMA-avid lesions in the prostate. However, 18F-PMSA-1007 pinpointed additional findings in four patients – three were confirmed as prostate cancer, and one was determined to be chronic prostatitis.

The results indicate an interchangeability between the radiopharmaceuticals, the team said.

“In view of the near-equal performance of the two traces, this preliminary study suggest the routine use of 18F-PMSA-1007 in lieu of 68Ga-PMSA-11 for staging prostate cancer patients, and clinicians can use either radiotracer based on availability,” the team wrote.

Related Videos
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Expediting the Management of Incidental Pulmonary Emboli on CT
Related Content
© 2023 MJH Life Sciences

All rights reserved.